Crosslinked ionizable lipids reprogram dendritic cell metabolism for potent mRNA vaccination
Source abstract
Abstract
Modulating metabolism in immune cells is an effective approach to induce desired immune responses. Here we develop a lipid nanoparticle (LNP) capable of metabolic reprogramming of dendritic cells for mRNA vaccine applications. Using imidoester-based conjugation chemistry, we design a crosslinked ionizable lipid, C12-2aN, which possesses intrinsic metabolic modulatory properties. This multifunctional ionizable lipid not only promotes effective mRNA expression by facilitating endosomal escape but also stimulates glycolysis through mTORC2 pathway activation. As both an mRNA carrier and a metabolic modulator, C12-2aN LNPs lead to potent vaccine efficacy in both SARS-CoV-2 and OVA cancer vaccine models, resulting in stronger neutralization of pseudovirus infection and improved survival rates, respectively, compared with control LNPs without the crosslinker. Moreover, C12-2aN LNPs outperformed FDA-approved LNPs in terms of reduced off-target delivery and lower immunogenicity. Overall, the integration of mRNA delivery and metabolic reprogramming induced by the ionizable lipid component presents significant potential for next-generation mRNA LNP vaccines.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Paludan, S. R., Pradeu, T., Masters, S. L. & Mogensen, T. H. Constitutive immune mechanisms: mediators of host defence and immune regulation. Nat. Rev. Immunol. 21, 137–150 (2021).10.1038/s41577-020-0391-5 ↗
2. Leone, R. D. & Powell, J. D. Metabolism of immune cells in cancer. Nat. Rev. Cancer 20, 516–531 (2020).10.1038/s41568-020-0273-y ↗
3. Jung, J., Zeng, H. & Horng, T. Metabolism as a guiding force for immunity. Nat. Cell Biol. 21, 85–93 (2019).10.1038/s41556-018-0217-x ↗
4. Ganeshan, K. & Chawla, A. Metabolic regulation of immune responses. Annu. Rev. Immunol. 32, 609–634 (2014).10.1146/annurev-immunol-032713-120236 ↗
5. Menk, A. V. et al. Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep. 22, 1509–1521 (2018).10.1016/j.celrep.2018.01.040 ↗
6. Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103–107 (2009).10.1038/nature08097 ↗
7. Kastenmüller, W., Kastenmüller, K., Kurts, C. & Seder, R. A. Dendritic cell-targeted vaccines—hope or hype?. Nat. Rev. Immunol. 14, 705–711 (2014).10.1038/nri3727 ↗
8. Giovanelli, P., Sandoval, T. A. & Cubillos-Ruiz, J. R. Dendritic cell metabolism and function in tumors. Trends Immunol. 40, 699–718 (2019).10.1016/j.it.2019.06.004 ↗
9. Pearce, E. J. & Everts, B. Dendritic cell metabolism. Nat. Rev. Immunol. 15, 18–29 (2015).10.1038/nri3771 ↗
10. Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 5408 (2019).10.1038/s41467-019-13368-y ↗
11. Everts, B. et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activation. Nat. Immunol. 15, 323–332 (2014).10.1038/ni.2833 ↗
12. Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709–722 (2024).10.1038/s41573-024-00977-6 ↗
13. Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L. & Peer, D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat. Rev. Clinc. Oncol. 20, 739–754 (2023).10.1038/s41571-023-00811-9 ↗
14. Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273–2287 (2022).10.1038/s41591-022-02061-1 ↗
15. Hou, Z., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 12, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
16. Hand, E. S. & Jencks, W. P. Mechanism of the reaction of imido esters with amines. J. Am. Chem. Soc. 84, 3505–3514 (1962).10.1021/ja00877a017 ↗
17. Hunter, M. J. & Ludwig, M. L. The reaction of imidoesters with proteins and related small molecules. J. Am. Chem. Soc. 84, 3419–3504 (1962).10.1021/ja00877a016 ↗
18. Liu, S. et al. Membrane destabilizing ionizable phospholipids for organ selective mRNA delivery and CRISPR/Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
19. Xu, Y. & Szoka, F. C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35, 5616–5623 (1996).10.1021/bi9602019 ↗
20. Zainal Abidin, A. et al. Amidine containing compounds: antimicrobial activity and its potential in combating antimicrobial resistance. Heliyon 10, e32010 (2024).10.1016/j.heliyon.2024.e32010 ↗
21. Sondi, S. M., Rani, R., Roy, P., Agrawal, S. K. & Saxena, A. K. Synthesis, anti-inflammatory, and anticancer activity evaluation of some heterocyclic amidine and bis-amidine derivatives. J. Heterocyclic. Chem. 48, 921–926 (2011).10.1002/jhet.658 ↗
22. Samsonowicz-Górski, J., Brodzka, A., Ostaszewski, R. & Koszelewski, D. Screening for amidoxime reductases in plant roots and Saccharomyces cerevisiae—development of biocatalytic method for chemoselective amidine synthesis. Bioorg. Chem. 124, 105815 (2022).10.1016/j.bioorg.2022.105815 ↗
23. Foretz, M., Guigas, B. & Viollet, B. Metformin: update on mechanisms of action and repurposing potential. Nat. Rev. Endocrinol. 19, 460–476 (2023).10.1038/s41574-023-00833-4 ↗
24. Jang, J. Y. et al. Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on PPARγ. Sci. Rep. 8, 31 (2018).10.1038/s41598-017-18274-1 ↗
25. Zhang, Z. et al. Brain-restricted mTOR inhibition with binary pharmacology. Nature 609, 822–828 (2022).10.1038/s41586-022-05213-y ↗
26. Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).10.1016/j.cell.2017.02.004 ↗
27. Kazyken, D. et al. AMPK directly activates mTORC2 to promote cell survival during acute energetic stress. Sci. Signal. 12, eaav3249 (2019).10.1126/scisignal.aav3249 ↗
28. Zhang, P. et al. WSSV exploits AMPK to activate mTORC2 signaling for proliferation by enhancing aerobic glycolysis. Commun. Biol. 6, 361 (2023).10.1038/s42003-023-04735-z ↗
29. Masui, K. et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 18, 726–739 (2013).10.1016/j.cmet.2013.09.013 ↗
30. Li, M. et al. mTORC2-AKT signaling to PFKFB2 activates glycolysis that enhances stemness and tumorigenicity of intestinal epithelial cells. FASEB J. 38, e23532 (2024).10.1096/fj.202301833RR ↗
31. Hagiwara, A. et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 15, 725–738 (2012).10.1016/j.cmet.2012.03.015 ↗
32. Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085–2096 (2023).10.1038/s12276-023-01086-x ↗
33. Margraf, A., Lowell, C. A. & Zarbock, A. Neutrophils in acute inflammation: current concepts and translational implications. Blood 139, 2130–2144 (2022).10.1182/blood.2021012295 ↗
34. Binici, B., Rattray, Z., Zinger, A. & Perrie, Y. Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: a combined in vitro and preclinical perspective. J. Control. Release 377, 162–173 (2025).10.1016/j.jconrel.2024.11.010 ↗
35. Zhang, W. et al. The expression kinetics and immunogenicity of lipid nanoparticles delivering plasmid DNA and mRNA in mice. Vaccines 11, 1580 (2023).10.3390/vaccines11101580 ↗
36. Yasmin, F. et al. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun. Inflamm. Dis. 11, e807 (2023).10.1002/iid3.807 ↗
37. Stylianopoulos, T. et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys. J. 99, 1342–1349 (2010).10.1016/j.bpj.2010.06.016 ↗
38. Dilliard, S. A., Chen, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).10.1073/pnas.2109256118 ↗
39. Møller, S. H., Wang, L. & Ho, P. C. Metabolic programming in dendritic cells tailors immune responses and homeostasis. Cell. Mol. Immunol. 19, 370–383 (2022).10.1038/s41423-021-00753-1 ↗
40. Brombacher, E. C. et al. AMPK activation induces RALDH+ tolerogenic dendritic cells by rewiring glucose and lipid metabolism. J. Cell Biol. 223, e202401024 (2024).10.1083/jcb.202401024 ↗
41. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).10.1073/pnas.0506580102 ↗
42. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).10.1016/j.cels.2015.12.004 ↗
43. Castanza, A. S. et al. Extending support for mouse data in the Molecular Signatures Database (MSigDB). Nat. Methods 20, 1619–1620 (2023).10.1038/s41592-023-02014-7 ↗
44. Ge, S. X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36, 2628–2629 (2020).10.1093/bioinformatics/btz931 ↗
45. Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).10.1038/s41592-019-0619-0 ↗